PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
LUNG vs. NVDA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between LUNG and NVDA is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

LUNG vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pulmonx Corporation (LUNG) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%SeptemberOctoberNovemberDecember2025February
16.96%
8.32%
LUNG
NVDA

Key characteristics

Sharpe Ratio

LUNG:

-0.52

NVDA:

1.64

Sortino Ratio

LUNG:

-0.47

NVDA:

2.18

Omega Ratio

LUNG:

0.95

NVDA:

1.28

Calmar Ratio

LUNG:

-0.42

NVDA:

3.44

Martin Ratio

LUNG:

-0.77

NVDA:

9.53

Ulcer Index

LUNG:

50.04%

NVDA:

9.76%

Daily Std Dev

LUNG:

74.59%

NVDA:

56.59%

Max Drawdown

LUNG:

-93.02%

NVDA:

-89.73%

Current Drawdown

LUNG:

-87.28%

NVDA:

-6.24%

Fundamentals

Market Cap

LUNG:

$262.20M

NVDA:

$3.41T

EPS

LUNG:

-$1.47

NVDA:

$2.53

Total Revenue (TTM)

LUNG:

$60.02M

NVDA:

$91.17B

Gross Profit (TTM)

LUNG:

$44.31M

NVDA:

$69.14B

EBITDA (TTM)

LUNG:

-$38.79M

NVDA:

$60.32B

Returns By Period

In the year-to-date period, LUNG achieves a 29.31% return, which is significantly higher than NVDA's 4.33% return.


LUNG

YTD

29.31%

1M

41.84%

6M

27.80%

1Y

-39.45%

5Y*

N/A

10Y*

N/A

NVDA

YTD

4.33%

1M

-0.51%

6M

13.25%

1Y

107.70%

5Y*

80.80%

10Y*

74.84%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

LUNG vs. NVDA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LUNG
The Risk-Adjusted Performance Rank of LUNG is 2323
Overall Rank
The Sharpe Ratio Rank of LUNG is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of LUNG is 2121
Sortino Ratio Rank
The Omega Ratio Rank of LUNG is 2222
Omega Ratio Rank
The Calmar Ratio Rank of LUNG is 2121
Calmar Ratio Rank
The Martin Ratio Rank of LUNG is 3030
Martin Ratio Rank

NVDA
The Risk-Adjusted Performance Rank of NVDA is 8888
Overall Rank
The Sharpe Ratio Rank of NVDA is 8989
Sharpe Ratio Rank
The Sortino Ratio Rank of NVDA is 8282
Sortino Ratio Rank
The Omega Ratio Rank of NVDA is 8181
Omega Ratio Rank
The Calmar Ratio Rank of NVDA is 9696
Calmar Ratio Rank
The Martin Ratio Rank of NVDA is 9191
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

LUNG vs. NVDA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Pulmonx Corporation (LUNG) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for LUNG, currently valued at -0.52, compared to the broader market-2.000.002.00-0.521.64
The chart of Sortino ratio for LUNG, currently valued at -0.47, compared to the broader market-4.00-2.000.002.004.006.00-0.472.18
The chart of Omega ratio for LUNG, currently valued at 0.95, compared to the broader market0.501.001.502.000.951.28
The chart of Calmar ratio for LUNG, currently valued at -0.42, compared to the broader market0.002.004.006.00-0.423.44
The chart of Martin ratio for LUNG, currently valued at -0.77, compared to the broader market-10.000.0010.0020.0030.00-0.779.53
LUNG
NVDA

The current LUNG Sharpe Ratio is -0.52, which is lower than the NVDA Sharpe Ratio of 1.64. The chart below compares the historical Sharpe Ratios of LUNG and NVDA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
-0.52
1.64
LUNG
NVDA

Dividends

LUNG vs. NVDA - Dividend Comparison

LUNG has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.02%.


TTM20242023202220212020201920182017201620152014
LUNG
Pulmonx Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVDA
NVIDIA Corporation
0.02%0.02%0.03%0.11%0.05%0.12%0.27%0.46%0.29%0.45%1.20%1.70%

Drawdowns

LUNG vs. NVDA - Drawdown Comparison

The maximum LUNG drawdown since its inception was -93.02%, roughly equal to the maximum NVDA drawdown of -89.73%. Use the drawdown chart below to compare losses from any high point for LUNG and NVDA. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-87.28%
-6.24%
LUNG
NVDA

Volatility

LUNG vs. NVDA - Volatility Comparison

Pulmonx Corporation (LUNG) has a higher volatility of 31.54% compared to NVIDIA Corporation (NVDA) at 24.11%. This indicates that LUNG's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
31.54%
24.11%
LUNG
NVDA

Financials

LUNG vs. NVDA - Financials Comparison

This section allows you to compare key financial metrics between Pulmonx Corporation and NVIDIA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab